{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-035847","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2025-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.725913+00:00","generated_at":"2026-05-18T02:24:56.189129+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vir doses first patient in Phase 1 trial of EGFR-TCE VIR-5525; triggers $75M milestone payment to Sanofi","bullets":["First patient dosed in Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR, in solid tumors (NSCLC, CRC, HNSCC, cSCC).","Dosing triggers a $75M milestone payment to Sanofi under the 2024 license agreement, recognized as R&D expense in Q3 2025.","$75M milestone was held as restricted cash and excluded from the $1.02B cash reported as of March 31, 2025.","Dose escalation continues for TCEs VIR-5818 (HER2) and VIR-5500 (PSMA) in heavily pretreated patients, showing early response signals.","VIR-5525 is Vir's third dual-masked TCE in clinical trials; preclinical candidates integrating PRO-XTEN and AI discovery are advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-035847","json":"https://secwatch.observer/filing/0001628280-25-035847.json","markdown":"https://secwatch.observer/filing/0001628280-25-035847.md","text":"https://secwatch.observer/filing/0001628280-25-035847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025035847/0001628280-25-035847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025035847/vir-20250724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T02:24:56.189129+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}